Singapore-based clinical-stage biotech Lion TCR announced the enrollment of the first subject in a clinical study for LioCyx-M004, its autologous T-cell therapy targeting HBV-related hepatocellular carcinoma (HCC). The therapy uses mRNA-engineered T-cells to recognize and destroy hepatitis B virus (HBV)-related liver cancer cells.
Therapy Details
LioCyx-M004 leverages Lion TCR’s RNA technology platform to express HBV-specific T-cell receptors (TCRs). Preclinical and clinical data show the therapy’s ability to selectively target and kill HBV-related liver cancer cells while maintaining a favorable safety profile. The therapy has received IND approvals in the U.S. and Singapore and has fast-track designation in the U.S.
Company Background
Lion TCR develops autologous and allogeneic cell therapies using its TCR discovery platform. Its pipeline includes programs targeting HCC and chronic HBV infection, with LioCyx-M004 representing a key milestone in its clinical development.-Fineline Info & Tech
